NCT05683834 2026-04-22
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
National Institutes of Health Clinical Center (CC)
University of Minnesota
University of Minnesota
Henogen